F.M. Mottaghy

Lenaerts, M., van Amstel, F. J. G., Mottaghy, F. M., Geurts, S. M. E., Tjan-Heijnen, V. C. G., Smidt, M. L., & van Nijnatten, T. J. A. (2025). A review of the association between baseline [18F] fluorodeoxyglucose uptake and axillary pathological complete response in node-positive breast cancer patients: focus on clinical subtypes. Nuclear medicine communications, 46(5), 384-391. https://doi.org/10.1097/MNM.0000000000001964

Juweid, M. E., Al-Qasem, S. F., Khuri, F. R., Gallamini, A., Lohmann, P., Ziellenbach, H.-J., & Mottaghy, F. M. (2025). Beyond fluorodeoxyglucose: Molecular imaging of cancer in precision medicine. Ca-A Cancer Journal for Clinicians, (3). Advance online publication. https://doi.org/10.3322/caac.70007

Kuppers, F., Kassem, M., Yun, S. D., Stoffels, G., Filss, C., Galldiks, N., Mottaghy, F. M., Kooi, M. E., Langen, K.-J., Lohmann, P., & Shah, N. J. (2025). Brain Tumor Characterization Using Multiple MR Parameters From Multi-Contrast EPI With Keyhole (GE-SE EPIK) Including Oxygen Extraction Fraction: A Comparison to O-(2-[18F]Fluoroethyl)-L-Tyrosine (FET) Positron Emission Tomography. Journal of Magnetic Resonance Imaging. Advance online publication. https://doi.org/10.1002/jmri.29795

Ceccon, G. S., Werner, J. M., Ruge, M. I., Goldbrunner, R., Celik, E., Baues, C., Deckert, M., Brunn, A., Rongen, M. M., Büttner, R., Dunkl, V., Nogova, L., Schlamann, M., Kabbasch, C., Rueß, D., Hampl, J., Wollring, M. M., Rosen, E. K., Tscherpel, C., ... Galldiks, N. (2025). The Value of Multidisciplinary Neuro-oncological Tumor Boards to Increase the Accuracy of FET PET for Identifying Brain Tumor Relapse. Clinical Nuclear Medicine, 50(4), 307-315. https://doi.org/10.1097/RLU.0000000000005634

Wang, Y., Barmin, R., Mottaghy, F. M., Kiessling, F., Lammers, T., & Pallares, R. M. (2025). Nanoparticles in nuclear medicine: From diagnostics to therapeutics. Journal of Controlled Release, 383, Article 113815. Advance online publication. https://doi.org/10.1016/j.jconrel.2025.113815

Friedrich, M., Werner, J.-M., Steinbach, J. P., Sabel, M., Herrlinger, U., Piroth, M., Stoffels, G., Filss, C. P., Lohmann, P., Shah, N. J., Ruge, M., Mottaghy, F. M., Goldbrunner, R., Langen, K.-J., Fink, G. R., Kocher, M., & Galldiks, N. (2025). Functional connectivity between tumor region and resting-state networks as imaging biomarker for overall survival in recurrent gliomas diagnosed by O-(2-[<SUP>18</SUP>F]fluoroethyl)-l-tyrosine PET. Neuro-Oncology Advances, 7(1), Article vdaf023. https://doi.org/10.1093/noajnl/vdaf023

Langen, K.-J., Stoffels, G., Filss, C. P., Kocher, M., Lerche, C., Sabel, M., Rapp, M., Noltemeier, H., Werner, J.-M., Ceccon, G., Wollring, M. M., Rosen, J., Steinbach, J. P., Hattingen, E., Weinzierl, M. R., Stoffel, M., Clusmann, H., Shah, N. J., Mottaghy, F. M., ... Lohmann, P. (2025). Borderline Findings in O-(2-[18F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice. Journal of Nuclear Medicine, 66(2), 187-193. https://doi.org/10.2967/jnumed.124.268768

Biersack, H. J., Rojas-Fernandez, A., Ting, H.-H., Kramer, V., Juweid, M. E., & Mottaghy, F. M. (2025). The promising potential of camelid nanobodies for nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging. Advance online publication. https://doi.org/10.1007/s00259-025-07136-y

Vaz, S. C., Groheux, D., van Nijnatten, T., Antunovic, L., Cardoso, F., Mottaghy, F., Cardoso, M. J., Riedl, C., de Geus-Oei, L.-F., & Ulaner, G. A. (2025). Editorial Commentary: Should "heterogeneous response" be considered as new category for assessing treatment response in patients with breast cancer? European Journal of Nuclear Medicine and Molecular Imaging, 52(3), 801-805. https://doi.org/10.1007/s00259-024-07042-9

Volnov, S., Baagil, H., Winz, O., Kaiser, H.-J., Meles, S. K., Schulz, J. B., Reetz, K., Mottaghy, F. M., & Holtbernd, F. (2025). Identification of a metabolic brain network characterizing essential tremor. Scientific Reports, 15(1), Article 2138. https://doi.org/10.1038/s41598-024-82069-4